Solubilized magnolol analogs

Inventors: Regina Hourigan (Metuchen, NJ); Jeffrey Mastrull (Flemington, NJ); Jairajh Mattai (Piscataway, NJ); James Masters (Ringoes, NJ)

Assignee: Cologne-Palmolive Company

A01N31/08 A01N25/02 A61K8/347 A61K8/4973 A61K8/4993 A61K8/86 A61Q11/00 A61Q11/02 A61Q19/10 A61K2800/49

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,414,587
App. No.: 14/362,903
Granted: Aug 16, 2016
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol and a sorbitan ester. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti-bacterial activity and reducing the expression of pro-inflammatory mediators. If isopropyl is selected, then the sorbitan ester is at least one of polyoxyethylene 20 sorbitan monooleate, and a proviso that if isobutyl magnolol is selected, then the sorbitan ester is poloxyethylene 20 sorbitan monooleate.

Claims (20)

1. A composition comprising a solubilized magnolol analog comprising:

at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol,

a sorbitan ester,

with a proviso that if isopropyl magnolol is selected, then the sorbitan ester is at least one of polyoxyethylene 20 sorbitan monolaurate and polyoxyethylene 20 sorbitan monooleate, and a proviso that if isobutyl magnolol is selected, then the sorbitan ester is polyoxyethylene 20 sorbitan monooleate;

wherein the magnolol analog is present in an amount of 0.01 to 5% by weight of the composition; and wherein the composition comprises:

(a) Isopropyl magnolol and 10 times its weight of polyoxyethylene 20 sorbitan monolaurate; or

(b) Isopropyl magnolol and 20 times its weight of polyoxyethylene 20 sorbitan monooleate; or

(d) Propyl magnolol and 10 times its weight of polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monooleate, or polyoxyethylene sorbitan trioleate; or

(e) Butyl magnolol and 10 times its weight of polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monooleate, or polyoxyethylene sorbitan trioleate.

2. The composition of claim 1 further comprising a surfactant.

3. The composition of claim 1 further comprising soap.

4. The composition of claim 3 in the form of a bar soap.

5. The composition of claim 2 in the form of a liquid cleanser.

6. The composition of claim 1 in the form of an oral care composition.

7. The composition of claim 1 , wherein the composition comprises propyl magnolol and 10 times its weight of polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monooleate, or polyoxyethylene sorbitan trioleate.

8. The composition of claim 1 , wherein the composition comprises isopropyl magnolol and 10 times its weight of polyoxyethylene 20 sorbitan monolaurate.

9. The composition of claim 1 , wherein the composition comprises butyl magnolol and 10 times its weight of polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monooleate, or polyoxyethylene sorbitan trioleate.

10. The composition of claim 1 , wherein the composition comprises isobutyl magnolol and 20 times its weight of polyoxyethylene 20 sorbitan monooleate.

11. The composition of claim 1 , wherein the the composition comprises isopropyl magnolol and 20 times its weight of polyoxyethylene 20 sorbitan monooleate.

Continuity (1)

Related Publication 20140328772A1 · Nov 6, 2014